Worldwide RNAi Therapeutics and Technologies Industry Report to 2035 – Key Market Trends and Forecasts – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “RNAi Market: Therapeutics and Technologies by Key Therapeutic Areas, Route of Administration, Leading Industry Players, Type of RNAi Molecule and Key Geographical Regions, 2022-2035” report has been added to ResearchAndMarkets.com’s offering.

This report features an extensive study of the current market landscape and the likely future potential; associated with the RNAi therapeutics market, over the next decade. The study also includes a detailed analysis of key drivers and trends within this evolving market.

RNAi therapeutics have garnered significant attention post the 2006 Nobel Prize that was awarded to Andrew Fire and Craig Mello for the discovery of RNA interference (RNAi). Subsequently, upon the approval of the first RNAi therapeutic, ONPATTRO, in 2018, the field has witnessed a further surge in activity. Since then, three more RNAi based therapies, namely (in chronological order of approval year) GIVLAARI (November 2019), LEQVIO (October 2020) and OXLUMOT (November 2020), have been approved by regulatory authorities.

In addition, over 200 RNAi drug candidates are being evaluated across several clinical trials for the treatment of a wide range of disease indications. The ongoing research and development efforts are driven by the various advantages offered by these molecules; these include higher efficacy and enhanced potency at reduced effector molecule concentrations, over other modalities based on the anti-sense approach. RNAi-based therapies have also been identified as potential candidates for the treatment of COVID-19.

However, despite the numerous benefits offered by RNAi therapies, developers often face concerns related to the stability and targeted delivery of their candidates. In order to mitigate the aforementioned challenges, several players have developed novel technologies and delivery systems to ensure target specific delivery of these molecules. Such advancements have allowed therapy developers to shift their focus towards the use of RNAi therapeutics. Initiatives are also being undertaken to explore the vast potential associated with such therapeutic modalities for the control of disease-associated gene expression.

In addition to effective gene silencing, these candidates can be deployed for applications related to precision medicine. Studies have also demonstrated the safety of RNAi therapeutics in systemic delivery, paving the way for systemic applications of the therapy. The high specificity, efficiency, and long term and stable gene silencing capabilities of RNAi therapeutics are believed to offer the potential to revolutionize the biopharmaceutical industry. As a result, several big pharma players have also undertaken various initiatives in this field of research. In the last five years, USD 8.5 billion has been invested to enable the advancement of ongoing research efforts.

Moreover, 3,000+ articles related to RNAi therapeutics and technologies have been published. It is also worth highlighting that over 2,100 patents have been filed / granted, highlighting the continuous pace of ongoing innovation in this field. Given the high research activity and ongoing technology advancements, the RNAi therapeutics market is poised to grow at a steady pace in the foreseen future.

Key Questions Answered

• Who are the key players engaged in the development of RNAi therapeutics?
• Which drugs are being evaluated across early and late stages of pipeline?
• Which are the key therapeutic areas targeted by RNAi therapeutics?
• Which technology platforms/delivery systems are being used for the development and delivery of RNAi therapeutics?
• What are the most active trial sites (in terms of number of clinical studies being conducted) related to RNAi therapeutics?
• Who are the key opinion leaders/experts engaged in the field of RNAi therapeutics?
• Which companies are actively filing patents to drive innovation in the field of RNAi therapeutics?
• What type of partnership models are commonly adopted by industry stakeholders?
• Who are the key investors in this domain?
• Which commercialization strategies are most commonly adopted by RNAi therapy developers, across different stages of product development?
• Who are the key service providers engaged in the RNAi therapeutics domain?
• How is the current and future market opportunity likely to be distributed across key market segments?

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET OVERVIEW

5. COMPETITIVE LANDSCAPE

6. COMPANY COMPETITIVENESS ANALYSIS

7. APPROVED AND LATE STAGE RNAi THERAPEUTICS

7.1. Chapter Overview

7.2. Onpattro

7.3. Givlaari

7.4. Leqvio

7.5. OxlumoT

7.6. Fitusiran

7.7. Vutrisiran

7.8. SYL 1001

7.9. Vigil-EWS

7.10. SR-061

7.11. Nedosiran

8. TECHNOLOGY PLATFORMS AND DELIVERY SYSTEMS

8.1. Chapter Overview

8.2. Components of RNAi Delivery Systems

9. TECHNOLOGY COMPETITIVENESS ANALYSIS

10. KEY THERAPEUTIC INDICATIONS

11. CLINICAL TRIAL ANALYSIS

12. KEY OPINION LEADERS

13. PATENT ANALYSIS

14. PUBLICATION ANALYSIS

15. RECENT PARTNERSHIPS

16. FUNDING AND INVESTMENT ANALYSIS

17. KEY COMMERCIALIZATION STRATEGIES

18. RNAi IN DIAGNOSTICS

19. SERVICE PROVIDERS FOR RNAi THERAPEUTICS

20. DEMAND ANALYSIS

21. MARKET SIZING AND OPPORTUNITY ANALYSIS

22. SWOT ANALYSIS

23. INTERVIEW TRANSCRIPT(S)

24. CONCLUSION

25. APPENDIX 1: TABULATED DATA

For more information about this report visit https://www.researchandmarkets.com/r/lfvksd

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900